NCT03509545

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Sarfez Pharmaceuticals, Inc. · Industry
• Sex: Male
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.

Detailed description

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on changes in body weight after two weeks of treatment. To compare the frequency and volume of urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic peptide between the two sets of patients.

Conditions

• Body Weight Changes

Interventions

Type	Name	Description
DRUG	CHF Patients: ER Torsemide 40 mg	ER Torsemide 40mg given once daily to CHF patients
DRUG	CHF Patients: Furosemide 40 mg	Stable CHF patients taking twice-daily 40 mg Furosemide

Timeline

• Start date: 2021-06-30
• Primary completion: 2022-06-30
• Completion: 2022-06-30
• First posted: 2018-04-26
• Last updated: 2024-04-25

Locations

1 site across 1 country: India

Regulatory

• FDA-regulated drug study